FN2 Earnings Intelligence
Eli Lilly and Company ratios (quarterly)
Eli Lilly and Company (LLY) Ratios (quarterly) derived from persisted SEC financial facts.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 9/30/2024 | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 est. | 9/30/2026 est. |
|---|---|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - | - | - |
| - Cash | $3,369 | $3,093.3 | $3,375.9 | $9,791.9 | $5,282 | - | - |
| + Debt | $31,119.7 | $38,515.9 | $39,903.8 | $42,506.6 | $43,370 | - | - |
| Enterprise Value | - | - | - | - | - | - | - |
| Revenue | $11,439.1 | $12,728.5 | $15,557.7 | $17,600.8 | $19,799 | $20,684.7 | $21,650.8 |
| % Growth | - | - | - | - | - | 33.0% | 23.0% |
| Gross Profit | $9,268.3 | $10,504.3 | $13,109.9 | $14,592.5 | $16,222 | - | - |
| % Margin | 81.0% | 82.5% | 84.3% | 82.9% | 81.9% | - | - |
| EBITDA | - | - | - | - | - | - | - |
| % Margin | - | - | - | - | - | - | - |
| Net Income | $970.3 | $2,759.3 | $5,660.5 | $5,582.5 | $7,396 | - | - |
| % Margin | 8.5% | 21.7% | 36.4% | 31.7% | 37.4% | - | - |
| Diluted EPS | $1.07 | $3.06 | $6.29 | $6.21 | $8.26 | $6.01 | $9.46 |
| % Growth | - | - | - | - | - | -4.5% | 52.4% |
| Operating Cash Flow | - | $1,665.6 | - | - | $5,333 | - | - |
| CapEx | - | $1,509.5 | - | - | $2,326 | - | - |
| Free Cash Flow | - | $156.1 | - | - | $3,007 | - | - |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 9/30/2024 | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 est. | 9/30/2026 est. |
|---|---|---|---|---|---|---|---|
| Revenue | $11,439.1 | $12,728.5 | $15,557.7 | $17,600.8 | $19,799 | $20,684.7 | $21,650.8 |
| Gross Profit | $9,268.3 | $10,504.3 | $13,109.9 | $14,592.5 | $16,222 | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Net Income | $970.3 | $2,759.3 | $5,660.5 | $5,582.5 | $7,396 | - | - |
| Diluted EPS | $1.07 | $3.06 | $6.29 | $6.21 | $8.26 | $6.01 | $9.46 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 9/30/2024 | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | $3,369 | $3,093.3 | $3,375.9 | $9,791.9 | $5,282 |
| Short-term Debt | $2,074.3 | $4,016.4 | $5,723.7 | $1,633 | $4,000 |
| Long-term Debt | $29,045.4 | $34,499.5 | $34,180.1 | $40,873.6 | $39,370 |
| Total Debt | $31,119.7 | $38,515.9 | $39,903.8 | $42,506.6 | $43,370 |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 9/30/2024 | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | $1,665.6 | - | - | $5,333 |
| Capital Expenditure | - | $1,509.5 | - | - | $2,326 |
| Free Cash Flow | - | $156.1 | - | - | $3,007 |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 9/30/2024 | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 |
|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - |
| Gross Margin | 81.0% | 82.5% | 84.3% | 82.9% | 81.9% |
| EBITDA Margin | - | - | - | - | - |
| Net Margin | 8.5% | 21.7% | 36.4% | 31.7% | 37.4% |
| FCF Margin | - | 1.2% | - | - | 15.2% |
| Diluted EPS Growth | - | - | - | - | - |